ES05.02 Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?
A. Ferris Lungevity Foundation, Bethesda, MD/US Background: The lung cancer treatment landscape has rapidly evolved over the past five years, with the U.S. Food and Drug Administration (FDA) approving more than 15 new treatments for advanced-stage non-small cell lung cancer (NSCLC)more than in the prior 15 years combined. However, for multiple reasons, including the routine use of overly restrictive eligibility criteria and the difficulty of opening clinical trials in community oncology settings, too many advanced-stage NSCLC patients are unable to participate in clinical trials. As a result, patients do not have early access to potentially life-saving treatments. LUN-Gevity Foundation is committed to making lung cancer clinical trials more patient-centric and accessible by streamlining the process of conducting studies. Approach: In 2015, LUNGevity Foundation began convening multi-stakeholder meetings, the LUNGevity Scientific and Clinical Research Roundtables (SCRTs,) in order to address this complex problem and determine innovative and timely solutions. These Roundtables bring together senior leaders of domestic and international regulatory agencies, clinicians, payers, patient advocates, patients, CROs and trial sponsors to ideate on the most pressing issues confronting the clinical trial landscape, focusing on lung cancer trials as case studies and pilots. The roundtables provide a platform for top officials across sectors to discuss challenges and develop concrete approaches for designing and executing clinical trials that facilitate patient participation and provide earlier access to promising new treatments. Progress to Date: Since its inception, the SCRT program has advanced progress in multiple important areas, developing multistakeholder working groups, hosting five in-person stakeholder meetings and three interactive webinars. These efforts have focused on the following workstreams aimed at improving clinical trials from the patient perspective: Streamlining Lung Cancer Clinical Trials: The goal of this roundtable series is to streamline clinical trials and make them more accessible to patients. The three active workstreams include: Expanding eligibility criteria to allow access to patients that have been historically excluded from lung cancer trials: -A manuscript was recently published in the Journal of Thoracic Oncology1 presenting recommendations from the multi-stakeholder Expanded Eligibility Working Group on relaxing eligibility criteria to include advanced-stage patients with brain metastasis, poor performance status, and prior malignancies. This Working Group has also identified outdated or unnecessary exclusion criteria frequently seen in lung cancer trial protocols, especially those that may no longer be relevant to current classes of drugs with new mechanisms of action. The group continues to work with regulators and industry partners to revise clinical trial protocols to ensure that such criteria are no longer included in lung cancer trials. Streamlining reporting of suspected unexpected serious adverse reactions (SUSARs) and adverse events. This Working Group has been cataloguing anticipated adverse drug events (ADRs) observed in clinical trials with a goal of advancing understanding of the different types of ADRs and how they should be reported to eliminate excessive and unnecessary reporting. Creating a prospective real-world control arm for a histological subtype of lung cancer, such as small cell lung cancer (SCLC), where the standard-of-care hasn't changed over the past few decades and the natural history of the disease is well-characterized. The goal of this effort is to reduce the numbers of patients needed to complete enrollment for certain trials and maximize the opportunities for patients to access novel therapies. The Working Group is collaborating with health informatics companies to develop and pilot this novel control arm for SCLC trials in the first-line setting. Patient-Reported Outcomes: Due to more patient centric health systems, there has been an increased use and interest in patient-reported outcomes (PROs) to include the patient's perspective in research and clinical practice. With Each healthcare system will have its own unique approach to ensuring access to innovative new therapies. In dealing with the reality of finite and scares resources, many countries have developed formal decision making bodies, undertaking Health Technology Assessment (HTA). These processes interrogate both clinical and health economic data. Ethical considerations and patient preference can also be taken in to account. Advocates can work with HTA agencies to ensure that the experience of the patient population impacted by the therapy under review, is part of the assessment. Where assessment processes are not present, advocates can also use the patient experience to work with policymakers in ensuring that a particular disease has enough resources devoted to it. Using Patient Experience in improving access to new therapies: Through patient experience, advocates have a voice in shaping the process whereby patients access new therapies. There is potential to input across the whole process e designing clinical trials; regulation/licencing; HTA and access procedures. Only people living with a particular health condition can truly describe the challenges they face and the impact that a new therapy will have upon them. Quality of life scores and clinical trial data do not fully reflect patient priorities on aspects of their health and wellbeing. Hence the reason that formal and informal processes have been developed to allow patient advocates to submit the patient perspective to decision makers. In so doing, advocates need to Know the process that is required in their own healthcare system e many Regulators (eg, the FDA) and HTA bodies offer information, training and support to advocates 1. Have the credibility to speak on behalf of their patient community -the ability to contact and survey appropriate patients. Cdn per month for recent lung cancer treatments, 1-4 cost can be an insurmountable barrier access for patients. Public coverage offers patients a chance at life-extending treatments that they may not have ability to access. Health Technology Assessment (HTA) bodies are called to answer the value of the new treatment within a context of responsibility to public taxpayer funds. The patient voice within this process is critical to give a "true" assessment of the disease burden which goes beyond ICER's, QALY's and include real world
